Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

Researchers examined how mental health affects the relationship between discrimination and patient-reported outcomes among a racially diverse cohort with systemic lupus erythematosus.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...

In a new study, right heart failure (RHF) hospitalizations of people with systemic lupus erythematosus (SLE) was associated with higher in-hospital mortality and non-fatal adverse outcomes. Lupus ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of ...

Please provide your email address to receive an email when new articles are posted on . Telitacicept yielded a positive response to the modified SLE Responder Index-4 vs. placebo. The drug is not yet ...

US FDA Rejects AstraZeneca's Easier-to-use Version Of Lupus Therapy AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an ...